Factors affecting U.S. manufacturers' decisions to produce vaccines - Although vaccine makers have concerns about today's high production costs, they are increasing their R&D investment

Health Affairs

Volumn 24, Issue 3, 2005, Pages 635-642

  Coleman, Margaret S ^a   Sangrujee, Nalinee ^b   Zhou, Fangjun ^a   Chu, Susan ^a  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^b Palladium Group   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHICKENPOX VACCINE; DIPHTHERIA PERTUSSIS TETANUS VACCINE; HAEMOPHILUS INFLUENZAE TYPE B VACCINE; HEPATITIS A VACCINE; HEPATITIS B VACCINE; INFLUENZA VACCINE; MEASLES MUMPS RUBELLA VACCINE; PNEUMOCOCCUS VACCINE; POLIOMYELITIS VACCINE; VACCINE;

ARTICLE; COST BENEFIT ANALYSIS; DISEASE CONTROL; DRUG COST; DRUG MANUFACTURE; DRUG MARKETING; DRUG RESEARCH; FOOD AND DRUG ADMINISTRATION; HUMAN; LICENSING; ORGANIZATION; PUBLIC HEALTH SERVICE; UNITED STATES;

CENTERS FOR DISEASE CONTROL AND PREVENTION (U.S.); CHILD, PRESCHOOL; DECISION MAKING, ORGANIZATIONAL; DRUG INDUSTRY; HUMANS; MOTIVATION; RESEARCH; UNITED STATES; VACCINES;

EID: 20044366421     PISSN: 02782715     EISSN: None     Source Type: Journal    
DOI: 10.1377/hlthaff.24.3.635     Document Type: Article

References (17)

1. National Vaccine Advisory Committee, "Strengthening the Supply of Routinely Recommended Vaccines in the United States: Recommendations from the National Vaccine Advisory Committee," Journal of the American Medical Association 290, no. 23 (2003): 3122-3128.
2. Centers for Disease Control and Prevention, National Immunization Program, "2005 Childhood and Adolescent Immunization Schedule," www.cdc.gov/nip/recs/child-schedule.htm (14 March 2005).
3. For more background, see M. Pauly et al., eds., Supplying Vaccine: An Economic Analysis of Critical Issues (Amsterdam, Oxford, Tokyo, Washington: IOS Press, 1996).
4. Institute of Medicine, Financing Vaccines in the Twenty-first Century: Assuring Access and Availability (Washington: National Academies Press, 2004);
5. and NVAC, "Strengthening the Supply."
6. Dealogic, Reuters, "Let's Make a Deal: Ten Largest Corporate Acquisitions," money.cnn.com/2004/04/26/news/international/aventis_sanofi/ lets_make_a_deal.gif (4 February 2005).
7. Annual financial reports: GlaxoSmithKline, 2004, www.gsk.com/financial/ financialreports.htm (10 February 2005);
8. and Sanofi-Aventis, Interim 2004, Annual 2003, en.sanofi-aventis.com/ investors/reports/P_investors_report.asp (11 March 2005).
9. "Notice to Readers: Delayed Supply of Influenza Vaccine and Adjunct ACIP Influenza Vaccine Recommendations for the 2000-01 Influenza Season," Morbidity and Mortality Weekly Report 49, no. 27 (2000): 619-622;
10. and CDC, National Immunization Program, "Why Were There Shortages?" October 2004, www.cdc.gov/nip/news/shortages/default.htm (4 February 2005).
11. The questionnaire/discussion guide is available as an online appendix; see content.healthaffairs.org/cgi/content/full/24/3/635/DC1.
12. There are international substitutes for U.S. vaccines. See Immunization Action Coalition, "Vaccines and Biologics," www.immunize.org/ izpractices/p5120.pdf (2 February 2005);
13. and World Health Organization, "United Nations Prequalified Vaccines," January 2005, www.who.int/vaccines-access/quahty/ un_prequalified/prequalvaccinesproducers.html (2 February 2005).
14. IOM, Financing Vaccines in the Twenty-first Century.
15. See CDC National Immunization Program, "Recommendations of the ACIP," October 2004, www.cdc.gov/nip/publications/ACIP-list.htm (7 February 2005).
16. U.S. Government Accountability Office, Childhood Vaccines: Ensuring an Adequate Supply Poses Continuing Challenges (Washington: GAO, September 2002).
17. M. Kremer, "Creating Markets for New Vaccines: Parts 1 and 2," NBER Working Papers nos. 7716 and 7717 (Cambridge, Mass.: National Bureau of Economic Research, 12 May 2000).